ResteLab https://restelab.com/wp Empowering healthcare with diagnostic support Fri, 12 Mar 2021 06:50:30 +0000 en-US hourly 1 https://wordpress.org/?v=6.1.6 Restalyst Signed Research Collaboration Agreement With The National University Of Malaysia https://restelab.com/wp/blog/2020/09/01/restalyst-signed-research-collaboration-agreement-with-the-national-university-of-malaysia/ https://restelab.com/wp/blog/2020/09/01/restalyst-signed-research-collaboration-agreement-with-the-national-university-of-malaysia/#respond Tue, 01 Sep 2020 06:49:00 +0000 http://restelab.com/wp/?p=1189

Project to investigate the use of ITIH3 biomarker in screening of individuals with gastric cancer risk

]]> https://restelab.com/wp/blog/2020/09/01/restalyst-signed-research-collaboration-agreement-with-the-national-university-of-malaysia/feed/ 0 PRESS RELEASE – Singapore’s Restalyst Develops Highly Sensitive COVID-19 Antibody Test Comparable To Market Leaders https://restelab.com/wp/blog/2020/08/24/press-release-singapores-restalyst-develops-highly-sensitive-covid-19-antibody-test-comparable-to-market-leaders/ https://restelab.com/wp/blog/2020/08/24/press-release-singapores-restalyst-develops-highly-sensitive-covid-19-antibody-test-comparable-to-market-leaders/#respond Mon, 24 Aug 2020 06:49:00 +0000 http://restelab.com/wp/?p=1187

Singapore biomedical firm Restalyst has developed a COVID-19 antibody test, COVID19N-REAAD™, which will be instrumental in establishing disease prevalence in populations and the exposure risk factors associated with infection. Press release was made to countries in APAC, EMEA & LATAM.

]]> https://restelab.com/wp/blog/2020/08/24/press-release-singapores-restalyst-develops-highly-sensitive-covid-19-antibody-test-comparable-to-market-leaders/feed/ 0 Restalyst Received Singapore HSA Provisional Authorization Approval For COVID19N-REAAD™ Anti-SARS-CoV-2 Nucleocapsid Protein IgG ELISA. https://restelab.com/wp/blog/2020/08/07/restalyst-received-singapore-hsa-provisional-authorization-approval-for-covid19n-reaad-anti-sars-cov-2-nucleocapsid-protein-igg-elisa/ https://restelab.com/wp/blog/2020/08/07/restalyst-received-singapore-hsa-provisional-authorization-approval-for-covid19n-reaad-anti-sars-cov-2-nucleocapsid-protein-igg-elisa/#respond Fri, 07 Aug 2020 06:47:00 +0000 http://restelab.com/wp/?p=1185

This is a product intended for qualitative detection of IgG antibodies to SARS-CoV-2 Nucleocapsid Protein in human serum and plasma.

]]> https://restelab.com/wp/blog/2020/08/07/restalyst-received-singapore-hsa-provisional-authorization-approval-for-covid19n-reaad-anti-sars-cov-2-nucleocapsid-protein-igg-elisa/feed/ 0 Restalyst Received The CE Mark For RAPIT COVID-19 IgM/IgG Test Kit And COVID19N-REAAD™ Anti-SARS-CoV-2 Nucleocapsid Protein IgG ELISA. https://restelab.com/wp/blog/2020/07/08/restalyst-received-the-ce-mark-for-rapit-covid-19-igm-igg-test-kit-and-covid19n-reaad-anti-sars-cov-2-nucleocapsid-protein-igg-elisa/ https://restelab.com/wp/blog/2020/07/08/restalyst-received-the-ce-mark-for-rapit-covid-19-igm-igg-test-kit-and-covid19n-reaad-anti-sars-cov-2-nucleocapsid-protein-igg-elisa/#respond Wed, 08 Jul 2020 06:42:00 +0000 http://restelab.com/wp/?p=1183 https://restelab.com/wp/blog/2020/07/08/restalyst-received-the-ce-mark-for-rapit-covid-19-igm-igg-test-kit-and-covid19n-reaad-anti-sars-cov-2-nucleocapsid-protein-igg-elisa/feed/ 0 Restalyst Received Singapore HSA Provisional Authorization Approval For RAPIT COVID-19 IgM/IgG Test Kit https://restelab.com/wp/blog/2020/07/01/restalyst-received-singapore-hsa-provisional-authorization-approval-for-rapit-covid-19-igm-igg-test-kit/ https://restelab.com/wp/blog/2020/07/01/restalyst-received-singapore-hsa-provisional-authorization-approval-for-rapit-covid-19-igm-igg-test-kit/#respond Wed, 01 Jul 2020 06:40:00 +0000 http://restelab.com/wp/?p=1181 This a lateral flow chromatography immunoassay intended for the qualitative detection and differentiation of IgM and IgG antibodies against SARS-CoV-2 in human plasma, serum, finger pricked whole blood or whole blood.

]]> https://restelab.com/wp/blog/2020/07/01/restalyst-received-singapore-hsa-provisional-authorization-approval-for-rapit-covid-19-igm-igg-test-kit/feed/ 0 Restalyst @ MEDICA 2019 https://restelab.com/wp/blog/2019/11/22/restalyst-medica-2019/ https://restelab.com/wp/blog/2019/11/22/restalyst-medica-2019/#respond Fri, 22 Nov 2019 06:39:00 +0000 http://restelab.com/wp/?p=1179 18-21 Nov 2019. Restalyst participated in Medica 2019 under the Singapore Pavilion to promote her innovative cancer tests to the world.

]]> https://restelab.com/wp/blog/2019/11/22/restalyst-medica-2019/feed/ 0 Restalyst Offered HCC-REAAD™ ERBB3 ELISA For Gastric Cancer Surveillance Study In Poland https://restelab.com/wp/blog/2019/07/11/restalyst-offered-hcc-reaad-erbb3-elisa-for-gastric-cancer-surveillance-study-in-poland/ https://restelab.com/wp/blog/2019/07/11/restalyst-offered-hcc-reaad-erbb3-elisa-for-gastric-cancer-surveillance-study-in-poland/#respond Thu, 11 Jul 2019 06:36:00 +0000 http://restelab.com/wp/?p=1176 https://restelab.com/wp/blog/2019/07/11/restalyst-offered-hcc-reaad-erbb3-elisa-for-gastric-cancer-surveillance-study-in-poland/feed/ 0 Restalyst @ MEDICA 2018 https://restelab.com/wp/blog/2018/10/10/restalyst-medica-2018/ https://restelab.com/wp/blog/2018/10/10/restalyst-medica-2018/#respond Wed, 10 Oct 2018 06:34:00 +0000 http://restelab.com/wp/?p=1174 12 – 15 Nov 2018

As part of its commitment to continuous innovation, Restalyst will be participating in Medica 2018.
Visit us at Singapore Pavilion Hall 3 Booth G74.

]]> https://restelab.com/wp/blog/2018/10/10/restalyst-medica-2018/feed/ 0 Restalyst Received Singapore HSA Approval For An Improved Version Of Its Gastric Cancer Screening Kit – GC-REAAD™ https://restelab.com/wp/blog/2018/08/20/restalyst-received-singapore-hsa-approval-for-an-improved-version-of-its-gastric-cancer-screening-kit-gc-reaad/ https://restelab.com/wp/blog/2018/08/20/restalyst-received-singapore-hsa-approval-for-an-improved-version-of-its-gastric-cancer-screening-kit-gc-reaad/#respond Mon, 20 Aug 2018 06:00:00 +0000 https://restelab.com/wp/?p=1170

GC-REAAD™, an in-vitro diagnostic medical device for the early detection of gastric cancer, was developed based on competitive ELISA platform in 2015. It was recently improved to a sandwich ELISA platform and approved by Singapore HSA.

 
]]> https://restelab.com/wp/blog/2018/08/20/restalyst-received-singapore-hsa-approval-for-an-improved-version-of-its-gastric-cancer-screening-kit-gc-reaad/feed/ 0 Singapore’s Restalyst develops new method to improve liver cancer diagnosis https://restelab.com/wp/blog/2017/11/10/singapores-restalyst-develops-new-method-to-improve-liver-cancer-diagnosis/ https://restelab.com/wp/blog/2017/11/10/singapores-restalyst-develops-new-method-to-improve-liver-cancer-diagnosis/#respond Fri, 10 Nov 2017 07:36:03 +0000 http://restelab.com/wp/?p=1092
Singapore’s Restalyst develops new method to improve liver cancer diagnosis

]]> https://restelab.com/wp/blog/2017/11/10/singapores-restalyst-develops-new-method-to-improve-liver-cancer-diagnosis/feed/ 0